An Open-label, Multi-drug, Multi-center Phase II Combination Study of AZD4635 in Patients with Prostate Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca Pharmaceuticals, LP
Start Date
June 3, 2020
End Date
April 16, 2024
Administered By
Duke Cancer Institute
Awarded By
AstraZeneca Pharmaceuticals, LP
Start Date
June 3, 2020
End Date
April 16, 2024